Liquidia Corporation to Report Full Year 2021 Financial Results on Thursday, March 17, 2022
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Liquidia Corporation (LQDA) announced it will report its full-year 2021 financial results on March 17, 2022. A conference call is scheduled for 8:30 a.m. ET to discuss these results and provide a corporate update. The call can be accessed via phone and will also be available for live streaming on Liquidia's website. The company specializes in biopharmaceuticals, particularly treatments for pulmonary hypertension, and has received tentative FDA approval for its product YUTREPIA™ (treprostinil) inhalation powder.
Positive
- Tentative FDA approval for YUTREPIA™ (treprostinil) inhalation powder indicates potential revenue growth.
- Scheduled conference call suggests transparency and communication with investors.
Negative
- None.
Details
News Market Reaction – LQDA
The recorded move for LQDA in the trading session of this news was +0.27%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MORRISVILLE, N.C., March 10, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its full year 2021 financial results on Thursday, March 17, 2022. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update.
The live call may be accessed by dialing 1-877-707-8711 (domestic) or 1-857-270-6219 (international) and entering the conference code: 1379421. A webcast of the call will be available on Liquidia’s website at https://liquidia.com/index.php/investors/events-and-presentations and archived for a period of 30 days thereafter.
About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT® Technology. The company operates through its two wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies has developed YUTREPIA™ (treprostinil) inhalation powder, which has received tentative approval from the FDA for the treatment of pulmonary arterial hypertension (PAH). Liquidia PAH provides the commercialization for pharmaceutical products to treat pulmonary disease, such as generic Treprostinil Injection. For more information, please visit www.liquidia.com.
Contact Information
Media & Investors:
Jason Adair
Senior Vice President, Corporate Development and Strategy
919.328.4400
jason.adair@liquidia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.